Wei Kang, MSc

PhD student
The University of Hong Kong, Hong Kong

Wei KANG joined the Centre for Safe Medication Practice and Research at the University of Hong Kong as a PhD student in 2020. Her research lies in the fields of pharmacoepidemiology and health economics. Her primary focus is on leveraging real-world data to address cancer-related challenges, including the effectiveness, safety, and economic burden of anticoagulants for patients with cancer-associated thrombosis. She also seeks to understand disease burdens and vaccine safety for patients with cancer. Over the past few years, she has published numerous papers in reputable journals.

Disclosure information not submitted.

Presentation(s):

• Comparison of switching to direct oral anticoagulants and continuous low-molecular-weight heparin in the treatment of cancer-associated venous thromboembolism in Taiwan

  Tuesday, August 27, 2024
  1:30 PM – 1:45 PM CEST